biotech / news / / GlobeNewswire
Regeneron also earns spot on Dow Jones Best-in-Class North America Index for six consecutive years.
Regeneron will provide its new gene therapy for genetic hearing loss for free in the U.S.
KEY POINTS
- Regeneron introduced new science-led 2030 responsibility goals detailed in its 2025 Responsibility Report.
- Together for CHANGE™ aims to genetically sequence 500,000 volunteers of African ancestry for genomics research.
- Regeneron ranks in the top 10% of its industry on major ESG ratings such as S&P Global and ISS ESG.
COMPANIES
Summarized by Newsio from GlobeNewswire. How we summarize →